MedTrace Logo

Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial

NCT00500279 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2007-07-12

No results posted yet for this study

Summary

To evaluate the effect of celecoxib use for 3 month after drug-eluting stent implantation

* on restenosis
* on clinical outcome such as target lesion revascularization, thrombotic event, myocardial infarction, death
* on inflammatory biomarkers

Conditions

  • Angioplasty, Transluminal, Percutaneous Coronary
  • Coronary Restenosis

Interventions

DRUG

Celecoxib

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hyosoo Kim, MD, PhD · Seoul National University Hospital

  • Bonkwon Koo, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Completion
2009-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500279 on ClinicalTrials.gov